Ann: Phase 2 PTSD Clinical Trial Fully Recruited, page-8

From the ASX:
"
Reporting of results of clinical trials should be made regardless of whether the outcome is positive or negative, and should be clear and unambiguous, specifically addressing the endpoints announced at the commencement of the trial."

and

"
Delay in disclosure raises particular Listing Rule issues, and companies need to be sure that the circumstances of any delay come within the terms of the exception to Listing Rule 3.1 contained in Listing Rule 3.1A."

They will need to release results immediately unless there is a good reason not to (under Listing Rule 3.0 - the three exceptions to the above are very unlikely to apply). We will see results as soon as ready